Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 162 | $110,093,809 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
19 Sep 2023 20:40 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 18 Sep 2023 | Sale | 27,468 | 53.55 | 1,470,911 | D |
09 Aug 2023 18:05 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 07 Aug 2023 | Sale | 55,300 | 58.79 | 3,251,087 | D |
20 Jul 2023 17:47 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 17 Jul 2023 | Sale | 1,842 | 65 | 119,730 | D |
16 Jun 2023 17:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 14 Jun 2023 | Sale | 3,592 | 65.01 | 233,516 | D |
16 Jun 2023 17:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 14 Jun 2023 | Sale | 44,035 | 64.37 | 2,834,533 | D |
16 Jun 2023 17:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 14 Jun 2023 | Sale | 34,227 | 63.35 | 2,168,280 | D |
19 Apr 2023 18:00 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 17 Apr 2023 | Sale | 10,000 | 63 | 630,000 | D |
30 Mar 2023 17:08 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 28 Mar 2023 | Sale | 10,183 | 54.01 | 549,984 | D |
30 Mar 2023 17:08 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 28 Mar 2023 | Sale | 5,421 | 54.86 | 297,396 | D |
13 Mar 2023 19:36 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 13 Mar 2023 | Sale | 346 | 44.29 | 15,324 | D |
13 Mar 2023 19:36 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 13 Mar 2023 | Sale | 6,998 | 45.08 | 315,470 | D |
13 Mar 2023 19:35 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 13 Mar 2023 | Sale | 423 | 44.05 | 18,633 | D |
13 Mar 2023 19:35 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 13 Mar 2023 | Sale | 3,335 | 45.1 | 150,408 | D |
13 Mar 2023 19:35 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 10 Mar 2023 | Sale | 1,800 | 42.74 | 76,932 | D |
13 Mar 2023 19:35 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 10 Mar 2023 | Sale | 6,750 | 43.5 | 293,625 | D |
13 Mar 2023 19:34 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 13 Mar 2023 | Sale | 476 | 44.15 | 21,015 | D |
13 Mar 2023 19:34 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 13 Mar 2023 | Sale | 6,868 | 44.99 | 308,991 | D |
13 Mar 2023 19:34 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 10 Mar 2023 | Sale | 2,500 | 42.52 | 106,300 | D |
13 Mar 2023 19:34 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 10 Mar 2023 | Sale | 14,208 | 43.2 | 613,786 | D |
13 Mar 2023 19:32 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 13 Mar 2023 | Sale | 258 | 44.14 | 11,388 | D |
13 Mar 2023 19:32 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 13 Mar 2023 | Sale | 5,324 | 44.97 | 239,420 | D |
13 Mar 2023 19:32 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 10 Mar 2023 | Sale | 2,700 | 42.52 | 114,804 | D |
13 Mar 2023 19:32 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 10 Mar 2023 | Sale | 12,963 | 43.17 | 559,613 | D |
13 Mar 2023 19:31 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 13 Mar 2023 | Sale | 1,412 | 44.08 | 62,241 | D |
13 Mar 2023 19:31 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 13 Mar 2023 | Sale | 19,153 | 45.06 | 863,034 | D |
13 Mar 2023 19:31 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 10 Mar 2023 | Sale | 6,805 | 42.51 | 289,281 | D |
13 Mar 2023 19:31 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 10 Mar 2023 | Sale | 34,965 | 43.28 | 1,513,285 | D |
03 Mar 2023 19:03 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 01 Mar 2023 | Sale | 7,241 | 50.01 | 362,122 | D |
27 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 24 Feb 2023 | Sale | 4,046 | 47.12 | 190,648 | D |
27 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 24 Feb 2023 | Sale | 7,906 | 47.14 | 372,689 | D |
27 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 24 Feb 2023 | Sale | 7,906 | 47.03 | 371,819 | D |
27 Feb 2023 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 24 Feb 2023 | Sale | 7,455 | 47.03 | 350,609 | D |
27 Feb 2023 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 24 Feb 2023 | Sale | 22,590 | 47.03 | 1,062,408 | D |
22 Feb 2023 20:05 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 21 Feb 2023 | Sale | 635 | 48.93 | 31,071 | D |
22 Feb 2023 20:05 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 21 Feb 2023 | Sale | 123 | 47.32 | 5,820 | D |
22 Feb 2023 20:05 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 21 Feb 2023 | Sale | 3,140 | 46.61 | 146,355 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 75 | 49.6 | 3,720 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 806 | 48.63 | 39,196 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 800 | 47.2 | 37,760 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 6,673 | 46.55 | 310,628 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 100 | 49.6 | 4,960 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 1,100 | 48.68 | 53,548 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 643 | 47.23 | 30,369 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 9,296 | 46.56 | 432,822 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 94 | 49.6 | 4,662 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 900 | 48.72 | 43,848 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 800 | 47.32 | 37,856 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 8,649 | 46.54 | 402,524 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 17 Feb 2023 | Sale | 1,689 | 50.59 | 85,447 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 17 Feb 2023 | Sale | 52,279 | 49.81 | 2,604,017 | D |
22 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 21 Feb 2023 | Sale | 251 | 49.6 | 12,450 | D |
22 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 21 Feb 2023 | Sale | 2,502 | 48.7 | 121,847 | D |
22 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 21 Feb 2023 | Sale | 2,200 | 47.35 | 104,170 | D |
22 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 21 Feb 2023 | Sale | 22,895 | 46.54 | 1,065,533 | D |
21 Dec 2022 16:06 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 19 Dec 2022 | Sale | 5,000 | 50.82 | 254,100 | D |
15 Dec 2022 19:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 13 Dec 2022 | Sale | 33,083 | 55 | 1,819,565 | D |
02 Dec 2022 19:14 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 01 Dec 2022 | Sale | 22,796 | 53.48 | 1,219,130 | D |
02 Dec 2022 19:14 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 01 Dec 2022 | Sale | 27,204 | 53.94 | 1,467,384 | D |
08 Nov 2022 16:12 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 07 Nov 2022 | Sale | 5,000 | 52.1117 | 260,558 | D |
08 Nov 2022 16:12 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 07 Nov 2022 | Sale | 5,000 | 52.4929 | 262,464 | D |
23 Sep 2022 21:01 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Sep 2022 | Sale | 33,303 | 45.39 | 1,511,623 | D |
23 Sep 2022 21:01 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Sep 2022 | Sale | 31,861 | 45.88 | 1,461,783 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)